SM
PROF

SG3 Management’s Profound Medical PROF Stock Holding History

SG3 Management’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,000
Closed -$818K – 1194
2021
Q2 		$818K Sell
50,000
-8,400
-14% -$156K 0.03% 528
2021
Q1 		$1.18M Hold
58,400
– – 0.03% 554
2020
Q4 		$1.2M Buy
58,400
+16,800
+40% +$309K 0.02% 515
2020
Q3 		$734K Buy
+41,600
New +$661K 0.03% 479

Other funds holding PROF

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SG3 Management's PROF Position: Q3 2021 in Review

SG3 Management sold out of Profound Medical (PROF) in Q3 2021, closing a stake of 37,500 shares — an estimated $614K sold.

SG3 Management first reported a position in PROF in Q3 2020 and held it in 4 quarters. The position peaked at $637K in Q4 2020. 46 funds tracked by Wall St. Rank hold PROF as of Q3 2021.

  • SG3 Management reported no remaining Profound Medical position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 37,500 Profound Medical shares in Q3 2021, an estimated $614K.
  • SG3 Management first reported a position in Profound Medical in Q3 2020 and held it in 4 quarters.
  • SG3 Management's Profound Medical position peaked at $637K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Profound Medical as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.